Agenus (AGEN) Expected to Announce Earnings on Monday

Agenus (NASDAQ:AGEN) will likely be issuing its Q4 2025 results before the market opens on Monday, March 16th. Analysts expect the company to announce earnings of ($1.27) per share and revenue of $28.0960 million for the quarter. Individuals can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Monday, March 16, 2026 at 9:30 AM ET.

Agenus Price Performance

AGEN opened at $3.10 on Friday. The company’s 50-day moving average is $3.25 and its 200 day moving average is $3.78. Agenus has a fifty-two week low of $1.38 and a fifty-two week high of $7.34. The firm has a market capitalization of $105.43 million, a P/E ratio of -1.46 and a beta of 1.57.

Analyst Ratings Changes

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Agenus in a research report on Monday, December 29th. Two equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Agenus has an average rating of “Hold” and an average price target of $14.50.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Vanguard Group Inc. raised its stake in shares of Agenus by 1.5% during the 3rd quarter. Vanguard Group Inc. now owns 2,569,533 shares of the biotechnology company’s stock worth $9,893,000 after purchasing an additional 36,983 shares during the period. Renaissance Technologies LLC grew its position in Agenus by 721.1% during the fourth quarter. Renaissance Technologies LLC now owns 543,546 shares of the biotechnology company’s stock valued at $1,707,000 after buying an additional 477,346 shares during the period. AQR Capital Management LLC grew its position in Agenus by 3,080.3% during the first quarter. AQR Capital Management LLC now owns 441,486 shares of the biotechnology company’s stock valued at $664,000 after buying an additional 427,604 shares during the period. Marshall Wace LLP purchased a new stake in Agenus during the second quarter worth about $1,976,000. Finally, Bank of America Corp DE increased its holdings in Agenus by 110.0% during the second quarter. Bank of America Corp DE now owns 420,678 shares of the biotechnology company’s stock worth $1,922,000 after buying an additional 220,327 shares during the last quarter. Institutional investors own 61.46% of the company’s stock.

Agenus Company Profile

Agenus, Inc (NASDAQ:AGEN) is a clinical-stage immuno-oncology company headquartered in Lexington, Massachusetts. The company focuses on the discovery and development of therapies designed to modulate the immune system’s response to cancer. Leveraging proprietary platforms in checkpoint modulation, vaccine technology and adjuvant systems, Agenus aims to deliver combination regimens that enhance antitumor activity across a variety of solid tumors and hematological malignancies.

Agenus’ pipeline includes monoclonal antibodies targeting immune checkpoints, cytokine-based therapeutics and vaccine candidates built on its engineered heat shock protein (HSP) platform.